ATTORNEY GENERAL KEITH G. KAUTZ URGES CONSUMERS TO CLAIM COMPENSATION FOR INFLATED GENERIC DRUG PRICES

Attorney General Keith G. Kautz, along with the Attorneys General of 47 other states and territories, announce preliminary approval of their plan to distribute funds to consumers following multiple settlements with drug manufacturers accused of conspiring to inflate prices of generic drugs.

CHEYENNE, Wyo. – Attorney General Keith G. Kautz is urging consumers to check their eligibility for compensation for certain generic drug purchases and to submit a claim for compensation by following the link here. This month, the U.S. District Court for the District of Connecticut granted preliminary approval of a plan, filed by Wyoming and a coalition of 47 other states and territories, to distribute settlement funds paid by generic drug manufacturers in exchange for settlement of claims that those companies illegally conspired to raise the prices of generic drugs. 

The coalition previously announced settlements with the manufacturers Glenmark, Lannett, Bausch, Apotex, Heritage, and Heritage’s parent company, Emcure, totaling approximately $96.5 million. The multistate coalition’s distribution plan aims to return millions of dollars from those settlement funds to those potentially harmed by the elevated prices of the generic drugs that are the subjects of those settlements.

If you purchased a generic drug listed here between May 2009 and December 2019, you may be eligible for compensation.

To determine your eligibility, call 1-866-290-0182 (Toll-Free), email info@AGGenericDrugs.com or visit www.AGGenericDrugs.com.

Wyoming is part of a coalition of nearly all states and territories engaged in a series of antitrust cases, starting first in 2016. The first complaint included Heritage and 17 other corporate defendants, two individual defendants, and 15 generic drugs. The second complaint was filed in 2019 against Teva Pharmaceuticals and 21 of the nation’s largest generic drug manufacturers. The complaint names 16 individual senior executive defendants. The third complaint, to be tried first, focuses on 80 topical generic drugs that account for billions of dollars of sales in the United States and names 26 corporate defendants and 10 individual defendants. The States filed a fourth complaint earlier this year, alleging that Novartis AG, Sandoz Group AG and Sandoz AG, are liable for Sandoz’s alleged conduct and for fraudulently transferring assets.  Seven pharmaceutical executives have been cooperating to support the States’ claims in these cases.

The above-mentioned cases stem from a series of investigations built on evidence from several cooperating witnesses at the core of the different conspiracies, millions of documents, and a massive phone record data base. Each complaint addresses a different set of drugs and defendants and lays out an interconnected web of competing industry executives who regularly met and communicated with each other, providing ample opportunity to form illegal agreements. The complaints note that defendants used terms like "fair share," "playing nice in the sandbox," and "responsible competitor" to unlawfully discourage competition, raise prices, and enforce an ingrained culture of collusion.

Alaska, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Northern Mariana Islands, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, U.S. Virgin Islands, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin also joined in today’s announcement.